Radiation-induced CD8 T-lymphocyte apoptosis predicts tumor sensitivity in head and neck cancer
Détails
ID Serval
serval:BIB_587D75EF9FD0
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Poster: résume de manière illustrée et sur une page unique les résultats d'un projet de recherche. Les résumés de poster doivent être entrés sous "Abstract" et non "Poster".
Collection
Publications
Institution
Titre
Radiation-induced CD8 T-lymphocyte apoptosis predicts tumor sensitivity in head and neck cancer
Titre de la conférence
ECCO 13, 13rd European Conference on Clinical Oncology and Cancer Nursing
Adresse
Paris, France, October 29-November 3, 2005
ISBN
1359-6349
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
3
Série
European Journal of Cancer. Supplement
Pages
402-403
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Background: The concept of expecting radiosensitive tumors in patients
genetically hypersensitive to radiation is not widely accepted. Here, we
aim to assess whether the tumors of patients with increased lymphocyte
apoptotic response with head and neck cancer have a better outcome than
their normoresponsive counterparts. Materials and
Methods: Seventy-five patients with head and neck cancer treated with
curative radiation therapy (RT) were included in the KFS 00539-91997/
SKL 00778-2-1999 prospective study aiming at assessing the value of
CD8 T-lymphocyte apoptosis in predicting intrinsic radiosensitivity. Male to
female ratio was 60/15, and median age was 59 years (35-85). Median
radiation dose was 66Gy (60-74.4 (administered in median 41 days
(37-58). Dose per fraction was 2 Gy in the majority of the patients (n = 70).
Prior to RT, all patients were tested using a rapid (48 h) apoptosis assay
where fresh blood samples were irradiated with 8 Gy X-rays. Lymphocytes
were collected and prepared for flow cytometric analysis. Apoptosis was
assessed by gradual degradation of DNA (sub-G1 peak on the DNA
histogram). Acute (CTC v2.0) and late (RTOG/EORTC) toxicities were
graded in all patients. Median follow-up period was 31 months (23-43).
Results: Following in vitro 8Gy irradiation, median radiation-induced CD8
apoptosis was 20.88% (5.69-57.00%). Radiation-induced CD8 apoptosis
significantly predicted grade 2 and 3 late effects. The area under the
curve of the receiver-operated characteristic curve (sensitivity versus
1-specificity) of CD8 apoptosis was 0.83. Median time to Iocoregional
relapse was 30 months (1-43 months). There were 13 Iocoregional
relapses among the 37 patients showing CD8 apoptosis below the median
compared to 5 of 38 who were above (p= 0.02). Two-year estimated
Iocoregional relapse rate was 31% (95% CI: 17-45%) versus 14% (95%
CI: 3-25%), respectively (p = 0.03).
Conclusions: In patients with head and neck cancer treated with definitive
or postoperative RT, in vivo apoptotic response of CD8 lymphocytes
depends on genetic radiosensitivity, and the tumor follows the same
genetic radiosensitivity of normal tissues. However, these findings should
be confirmed prospectively, and future dose escalation studies could be
stratified using the apoptosis assay.
genetically hypersensitive to radiation is not widely accepted. Here, we
aim to assess whether the tumors of patients with increased lymphocyte
apoptotic response with head and neck cancer have a better outcome than
their normoresponsive counterparts. Materials and
Methods: Seventy-five patients with head and neck cancer treated with
curative radiation therapy (RT) were included in the KFS 00539-91997/
SKL 00778-2-1999 prospective study aiming at assessing the value of
CD8 T-lymphocyte apoptosis in predicting intrinsic radiosensitivity. Male to
female ratio was 60/15, and median age was 59 years (35-85). Median
radiation dose was 66Gy (60-74.4 (administered in median 41 days
(37-58). Dose per fraction was 2 Gy in the majority of the patients (n = 70).
Prior to RT, all patients were tested using a rapid (48 h) apoptosis assay
where fresh blood samples were irradiated with 8 Gy X-rays. Lymphocytes
were collected and prepared for flow cytometric analysis. Apoptosis was
assessed by gradual degradation of DNA (sub-G1 peak on the DNA
histogram). Acute (CTC v2.0) and late (RTOG/EORTC) toxicities were
graded in all patients. Median follow-up period was 31 months (23-43).
Results: Following in vitro 8Gy irradiation, median radiation-induced CD8
apoptosis was 20.88% (5.69-57.00%). Radiation-induced CD8 apoptosis
significantly predicted grade 2 and 3 late effects. The area under the
curve of the receiver-operated characteristic curve (sensitivity versus
1-specificity) of CD8 apoptosis was 0.83. Median time to Iocoregional
relapse was 30 months (1-43 months). There were 13 Iocoregional
relapses among the 37 patients showing CD8 apoptosis below the median
compared to 5 of 38 who were above (p= 0.02). Two-year estimated
Iocoregional relapse rate was 31% (95% CI: 17-45%) versus 14% (95%
CI: 3-25%), respectively (p = 0.03).
Conclusions: In patients with head and neck cancer treated with definitive
or postoperative RT, in vivo apoptotic response of CD8 lymphocytes
depends on genetic radiosensitivity, and the tumor follows the same
genetic radiosensitivity of normal tissues. However, these findings should
be confirmed prospectively, and future dose escalation studies could be
stratified using the apoptosis assay.
Mots-clé
,
Web of science
Création de la notice
28/04/2008 11:35
Dernière modification de la notice
20/08/2019 15:12
Données d'usage
